258 related articles for article (PubMed ID: 26046312)
1. Design, synthesis and biological evaluation of novel 4-alkynyl-quinoline derivatives as PI3K/mTOR dual inhibitors.
Lv X; Ying H; Ma X; Qiu N; Wu P; Yang B; Hu Y
Eur J Med Chem; 2015 Jun; 99():36-50. PubMed ID: 26046312
[TBL] [Abstract][Full Text] [Related]
2. Structural optimization towards promising β-methyl-4-acrylamido quinoline derivatives as PI3K/mTOR dual inhibitors for anti-cancer therapy: The in vitro and in vivo biological evaluation.
He R; Xu B; Ping L; Lv X
Eur J Med Chem; 2021 Mar; 214():113249. PubMed ID: 33561608
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel quinoline-based mTOR inhibitors via introducing intra-molecular hydrogen bonding scaffold (iMHBS): The design, synthesis and biological evaluation.
Ma X; Lv X; Qiu N; Yang B; He Q; Hu Y
Bioorg Med Chem; 2015 Dec; 23(24):7585-96. PubMed ID: 26596710
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
Peng W; Tu ZC; Long ZJ; Liu Q; Lu G
Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167
[TBL] [Abstract][Full Text] [Related]
5. New quinoline/chalcone hybrids as anti-cancer agents: Design, synthesis, and evaluations of cytotoxicity and PI3K inhibitory activity.
Abbas SH; Abd El-Hafeez AA; Shoman ME; Montano MM; Hassan HA
Bioorg Chem; 2019 Feb; 82():360-377. PubMed ID: 30428415
[TBL] [Abstract][Full Text] [Related]
6. PI3Kδ and mTOR dual inhibitors: Design, synthesis and anticancer evaluation of 3-substituted aminomethylquinoline analogues.
Yevale D; Teraiya N; Lalwani T; Dalasaniya M; Kapadiya K; Ameta RK; Sangani CB; Duan YT
Bioorg Chem; 2024 Jun; 147():107323. PubMed ID: 38583254
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides as PI3K/mTOR dual inhibitors.
Zhang J; Lv X; Ma X; Hu Y
Eur J Med Chem; 2017 Feb; 127():509-520. PubMed ID: 28109945
[TBL] [Abstract][Full Text] [Related]
8. Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor.
Han J; Chen Y; Yang C; Liu T; Wang M; Xu H; Zhang L; Zheng C; Song Y; Zhu J
Eur J Med Chem; 2016 Oct; 122():684-701. PubMed ID: 27448924
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel condensed pyrrolo[1,2-c]pyrimidines featuring morpholine moiety as PI3Kα inhibitors.
Ibrahim MA; Abou-Seri SM; Hanna MM; Abdalla MM; El Sayed NA
Eur J Med Chem; 2015 Jun; 99():1-13. PubMed ID: 26037808
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis and Biological Evaluation of Novel Benzothiazole Derivatives as Selective PI3Kβ Inhibitors.
Cao S; Cao R; Liu X; Luo X; Zhong W
Molecules; 2016 Jul; 21(7):. PubMed ID: 27384552
[TBL] [Abstract][Full Text] [Related]
11. Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602.
Poulsen A; Nagaraj H; Lee A; Blanchard S; Soh CK; Chen D; Wang H; Hart S; Goh KC; Dymock B; Williams M
J Chem Inf Model; 2014 Nov; 54(11):3238-50. PubMed ID: 25317974
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and docking studies of novel thienopyrimidine derivatives bearing chromone moiety as mTOR/PI3Kα inhibitors.
Zhu W; Chen C; Sun C; Xu S; Wu C; Lei F; Xia H; Tu Q; Zheng P
Eur J Med Chem; 2015 Mar; 93():64-73. PubMed ID: 25659752
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, biological evaluation and docking studies of novel 2-substituted-4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as dual PI3Kα/mTOR inhibitors.
Lei F; Sun C; Xu S; Wang Q; OuYang Y; Chen C; Xia H; Wang L; Zheng P; Zhu W
Eur J Med Chem; 2016 Jun; 116():27-35. PubMed ID: 27043268
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological activity of pyridopyrimidine scaffolds as novel PI3K/mTOR dual inhibitors.
Saurat T; Buron F; Rodrigues N; de Tauzia ML; Colliandre L; Bourg S; Bonnet P; Guillaumet G; Akssira M; Corlu A; Guillouzo C; Berthier P; Rio P; Jourdan ML; Bénédetti H; Routier S
J Med Chem; 2014 Feb; 57(3):613-31. PubMed ID: 24345273
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition.
Han Y; Tian Y; Wang R; Fu S; Jiang J; Dong J; Qin M; Hou Y; Zhao Y
Bioorg Chem; 2020 Nov; 104():104197. PubMed ID: 32927132
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and SAR of new-di-substituted pyridopyrimidines as ATP-competitive dual PI3Kα/mTOR inhibitors.
Al-Ashmawy AAK; Ragab FA; Elokely KM; Anwar MM; Perez-Leal O; Rico MC; Gordon J; Bichenkov E; Mateo G; Kassem EMM; Hegazy GH; Abou-Gharbia M; Childers W
Bioorg Med Chem Lett; 2017 Jul; 27(14):3117-3122. PubMed ID: 28571824
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR.
Hu J; Zhang Y; Tang N; Lu Y; Guo P; Huang Z
Bioorg Med Chem; 2021 Feb; 32():115997. PubMed ID: 33440319
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
Wurz RP; Liu L; Yang K; Nishimura N; Bo Y; Pettus LH; Caenepeel S; Freeman DJ; McCarter JD; Mullady EL; Miguel TS; Wang L; Zhang N; Andrews KL; Whittington DA; Jiang J; Subramanian R; Hughes PE; Norman MH
Bioorg Med Chem Lett; 2012 Sep; 22(17):5714-20. PubMed ID: 22832322
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and antitumor activity of novel thiophene- triazine derivatives bearing arylurea unit as potent PI3K/mTOR inhibitorss.
Xu S; Luo L; Sun X; Yang Y; Guo Q; Jiang Z; Wu Y
Bioorg Med Chem; 2023 Jan; 78():117133. PubMed ID: 36599263
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors.
Fan YH; Li W; Liu DD; Bai MX; Song HR; Xu YN; Lee S; Zhou ZP; Wang J; Ding HW
Eur J Med Chem; 2017 Oct; 139():95-106. PubMed ID: 28800461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]